- Home
- SAGE vs NEWT Comparison
SAGE vs NEWT Comparison
Compare SAGE & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- NEWT
- Stock Information
- Founded
- SAGE 2010
- NEWT 1998
- Country
- SAGE United States
- NEWT United States
- Employees
- SAGE N/A
- NEWT N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- NEWT Major Banks
- Sector
- SAGE Health Care
- NEWT Finance
- Exchange
- SAGE Nasdaq
- NEWT Nasdaq
- Market Cap
- SAGE 415.0M
- NEWT 335.7M
- IPO Year
- SAGE 2014
- NEWT N/A
- Fundamental
- Price
- SAGE $7.79
- NEWT $10.83
- Analyst Decision
- SAGE Hold
- NEWT Hold
- Analyst Count
- SAGE 19
- NEWT 4
- Target Price
- SAGE $9.88
- NEWT $14.50
- AVG Volume (30 Days)
- SAGE 1.2M
- NEWT 309.5K
- Earning Date
- SAGE 04-29-2025
- NEWT 05-06-2025
- Dividend Yield
- SAGE N/A
- NEWT 7.09%
- EPS Growth
- SAGE N/A
- NEWT 4.25
- EPS
- SAGE N/A
- NEWT 1.96
- Revenue
- SAGE $41,243,000.00
- NEWT $338,730,000.00
- Revenue This Year
- SAGE $100.64
- NEWT N/A
- Revenue Next Year
- SAGE $70.19
- NEWT $15.38
- P/E Ratio
- SAGE N/A
- NEWT $5.54
- Revenue Growth
- SAGE N/A
- NEWT 24.93
- 52 Week Low
- SAGE $4.62
- NEWT $9.12
- 52 Week High
- SAGE $14.97
- NEWT $15.49
- Technical
- Relative Strength Index (RSI)
- SAGE 56.30
- NEWT 47.96
- Support Level
- SAGE $7.56
- NEWT $9.93
- Resistance Level
- SAGE $7.89
- NEWT $11.07
- Average True Range (ATR)
- SAGE 0.36
- NEWT 0.57
- MACD
- SAGE 0.06
- NEWT 0.13
- Stochastic Oscillator
- SAGE 88.03
- NEWT 87.69
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions, It has developed a financial and technology-based business model that enables itself to acquire and process its clients in a very cost-effective manner. This capability is supported in large part by NewTracker, its patented prospect management technology software, that will allow NewtekOne clients to easily interact with NewtekOne subject matter experts in the areas of Banking, Lending, Payments, Technology, Payroll, and Insurance. It offers NewtekOne's clients a single online dashboard to access all of NewtekOne's business and financial solutions. It has four reportable segments Banking, Technology, NSBF, and Payments.